New Medication for High Cholesterol Not Cost-Effective
A new study in JAMA evaluated the cost-effectiveness of PCSK9 inhibitors and how increased use might affect the U.S. healthcare system.
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
